Afuresertib - Laekna Therapeutics
Alternative Names: 2110183; Afuresertib hydrochloride; ASB-183; GSK-2110183; GSK2110183B; GSK2110183C; LAE 002Latest Information Update: 27 Jun 2024
At a glance
- Originator GlaxoSmithKline
- Developer GSK; Laekna Therapeutics; Novartis Oncology; University Health Network
- Class Amides; Antineoplastics; Fluorobenzenes; Pyrazoles; Small molecules; Thiophenes
- Mechanism of Action Proto-oncogene protein c-akt inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III HER2 negative breast cancer
- Phase II Ovarian cancer
- Phase I/II Prostate cancer; Solid tumours
- Discontinued Cancer; Chronic lymphocytic leukaemia; Gastric cancer; Haematological malignancies; Histiocytosis; Multiple myeloma
Most Recent Events
- 17 Jun 2024 Phase-III clinical trials in HER2-negative-breast-cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO) prior to June 2024 (NCT04851613)
- 17 Jun 2024 Phase-III clinical trials in HER2-negative-breast-cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) prior to June 2024 (NCT04851613)
- 23 May 2024 US FDA approves IND application for phase-III trial for Afuresertib in Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease, Second-line therapy or greater)